[1]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2018［J］.CA Cancer J Clin,2018,68（1）:7-30.
[2]BABJUK M,BOHLE A,BURGER M,et al.EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder:update 2016 ［J］.Eur Urol,2017,71(3):447-461.
[3]SIEGEL RL,MILLER KD,JEMAL A.Cancer statistics,2020［J］.CA Cancer J Clin,2020,70:7-30.
[4]PARK JC,CITRIN DE,AGARWAL PK,et al.Mutimodal management of muscle invasive bladder cancer ［J］.Curr Probl Cancer,2014,38(3):80-108.
[5]RAMOS JD,YU EY.Making urothelial carcinomas less immune to immunotherapy［J］.Urol Oncol,2016,34(12):534-537.
[6]SMITH SG,ZAHAROFF DA.Future directions in bladder cancer immunotherapy:towards adaptive immunity［J］.Immunotherapy,2016,8(3):351-365.
[7]DUNN GP,BRUCE AT,IKEDA H,et al.Cancer immunoediting:from immunosurveillance to tumor escape［J］.Nat Immunol,2002,3:991-98.
[8]RIBATTI D.The concept of immune surveillance against tumors.The first theories［J］.Oncotarget,2017,8(4):7175-7180.
[9]GUIBERT N,DELAUNAY M,MAZIERES J.Targeting the immune system to treat lung cancer:rationale and clinical experience［J］.Ther Adv Respir Dis,2015,9(3):105-120.
[10]YARCHOAN M,HOPKINS A,JAFFEE EM.Tumor mutational burden and response rate to PD-1 inhibition［J］.N Engl J Med,2017,377(25):2500-2501.
[11]REDELMAN-SIDI G,GLICKMAN MS,BOCHNER BH.The mechanism of action of BCG therapy for bladder cancer-a current perspective［J］.Nat Rev Urol,2014,11:153-162.
[12]HERR HW,MORALES A.History of bacillus Calmette-Guerin and bladder cancer:an immunotherapy success story［J］.J Urol,2008,179(1):53-56.
[13]LORIOT Y,ROUPRE TM.Immunothe rapie des tumeurs de la vessie n'infiltrant pas le muscle:immunothe rapies et TVNIM.Immunotherapies in non-muscle invasive bladder cancer:immunotherapies and NMIBC［J］.Bull Cancer,2020,107(5S):S49-S55.
[14]ALFRED WITJES J,LEBRET T,COMPERAT EM,et al.Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer［J］.Eur Urol,2017,71:462-475.
[15]KAMAT AM,FLAIG TW,GROSSMAN HB,et al.Expert consensus document:consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer［J］.Nat Rev Urol,2015,12:225-235.
[16]BALAR AV,KULKARNI GS,UCHIO EM,et al.Keynote 057:Phase Ⅱ trial of pembrolizumab(pembro)for patients(pts)with high-risk(HR)nonmuscle invasive bladder cancer(NMIBC)unresponsive to bacillus calmette-gue′rin(BCG)［J］.Clin Oncol,2019,37(7):350-358.
[17]WIT RD,KULKARNI GS,UCHIO EM,et al.Pembrolizu-mab(Pembro) for patients(pts) with high-risk(HR) non-muscle invasive bladder cancer(NMIBC) unre-sponsive to Bacillus Calmette-Guerin(BCG):up-dated follow-up from KEYNOTE-057［J］.J Clin Oncol,2019,37:4530.
[18]WRIGHT KM.FDA approves pembrolizumab for BCG-unresponsive NMIBC［J］.Oncology(Williston Park),2020,34(2):44.
[19]FLAIG TW,SPIESS PE,AGARWAL N,et al.Bladder cancer,version 3.2020,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2020,18(3):329-354.
[20]BALAR AV,CASTELLANO D,O' DONNELL PH,et al.First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer(KEYNOTE-052):a multicentre,single-arm,phase 2 study［J］.Lancet Oncol,2017,18:1483-1492.
[21]BALAR AV,GALSKY MD,ROSENBERG JE,et al.Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma:a single-arm,multicentre,phase 2 trial［J］.Lancet,2017,389:67-76.
[22]SUZMAN DL,AGRAWAL S,NING YM,et al.FDA Approvalsummary:atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy［J］.Oncologist,2019,24(4):563-569.
[23]GALSKY MD,ARIJA JAA,BAMIAS A,et al.Atezolizumab with or without chemotherapy in metastatic urothelial cancer(IMvigor130):a multicentre,randomised,placebo-controlled phase 3 trial［J］.Lancet,2020,395(10236):1547-1557.
[24]POWLES T,RODRIGUEZ-VIDA A,DURAN I,et al.A phaseⅡStudy investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer(ABACUS)［J］.J Clin Oncol,2018,36(15):4506-4508.
[25]GRANDE E,GALSKY M,ARIJA JA,et al.IMvigor130:Efficacy and safety from a phase Ⅲ study of atezolizumab(atezo)as monotherapy or combined with platinum-based chemotherapy(PBC)vs placebot PBC in previously un-treated locally advanced or metastatic urothelial carcinoma(mUC)［J］.Annals of Oncology,2019,30:888-889.
[26]WU S,ADAMSON AS.Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma［J］.Dermatol Online,2019,25(2):13030.
[27]ROSENBERG JE,O'DONNELL PH,BALAR AV,et al.Pivotaltrial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy［J］.J Clin Oncol,2019,37(29):2592-2600.
[28]FRADET Y,BELLMUNT J,VAUGHN DJ,et al.Randomized phase Ⅲ KEYNOTE045 trial of pembrolizumab versus paclitaxel,docetaxel,or vinflunine in recurrent advanced urothelial cancer:results of 2 years of follow-up［J］.Ann Oncol,2019,30:970-976.
[29]NECCHI A,JOSEPH RW,LORIOT Y,et al.Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma:post-progression outcomes from the phase Ⅱ IMvigor210 study［J］.Ann Oncol,2017,28:3044-3050.
[30]STERNBERG CN,LORIOT Y,JAMES N,et al.Primary results from SAUL,a multinational ingle-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract［J］.Eur Urol,2019,76:73-81.
[31]LEE A,KEAM SJ.Tislelizumab:First Approval［J］.Drugs,2020,80(6):617-624.
[32]百泽安（替雷利珠单抗注射液）获批新适应证［J］.上海医药,2020,41(09):52.
BAIZEAN(Tilelizumab Injection)was approved for new indications［J］.Shanghai Medicine,2020,41(09):52.
[33]NECCHI A,MARIANI L,ANICHINI A,et al.Pembrolizumab and nanoparticle albumin bound paclitaxel(nab-paclitaxel)for metastatic urothelial carcinoma(UC)after chemotherapy failure:The open-label,single-arm,phase 2 PEANUT study［J］.European Urology Supplements,2017,16(10):2796.
[34]GROSS-GOUPIL M,DOMBLIDES C,LEFORT F,et al.Open-label randomized multi-center phase 2 study:gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma:GCisAve［J］.Bull Cancer,2020,107(5S):eS1-eS7.
[35]NECCHI A,BANDINI M,CALARESO G,et al.Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer:preliminary findings from the PURE-01 study［J］.Eur Urol,2020,77(5):636-643.
[36]POWLES T,KOCKX M,ODRIGUEZ-VIDA A,et al.Publisher correction:clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial［J］.Nat Med,2020,26(6):983.
[37]SCHMID SC,KOLL FJ,BECKERT F,SEITZ AK.Immunonkologische Ansatze in der perioperativen therapie des muskelinvasiven urothelkarzinoms.Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer［J］.Urologe A,2020,59(7):790-796.
[38]THIBAULT C,ELAIDI R,VANO YA,et al.Open-label phase Ⅱ to evaluate the efficacy of NEoadjuvant dose-dense MVAC In Ombination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma:NEMIO［J］.Bull Cancer,2020,107(5S):eS8-eS15.
[39]HASLAM A,PRASAD V.Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs［J］.JAMA Netw Open,2019,2(5):e192535.
[40]FARAJ SF,MUNARI E,GUNER G,et al.Assessment of tumoral PD-L1 expression and intratumoral CD8+T cells in urothelial carcinoma［J］.Urology,2015,85(3):703.e701-703.
[41]ALEXANDROV LB,NIK-ZAINAL S,WEDGE DC,et al.Signatures of mutational processes in human cancer ［J］.Nature,2013,500(7463):415-421.
[42]YARCHOAN M,HOPKINS A,JAFFEE EM.Tumor mutational burden and response rate to PD-1 inhibition［J］.N Engl J Med,2017,377(25):2500-2501.
[43]ZHU G,PEI L,LI Y,et al.EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients［J］.Aging(Albany NY),2020,12(3):2132-2141.
[44]DUDLEY JC,LIN MT,LE DT,ESHLEMAN JR.Microsatellite instability as a biomarker for PD-1 blockade［J］.Clin Cancer Res,2016,22(4):813-820.
[45]SHARMA P,RETZ M,SIEFKER-RADTKE A,et al.Nivolumab in metastatic urothelial carcinoma after platinum therapy(CheckMate 275):a multicentre,single-arm,phase 2 trial［J］.Lancet Oncol,2017,18(3):312-322.
[46]XU Y,WU G,LI J,et al.Screening and identification of key biomarkers for bladder cancer:a study based on TCGA and GEO data［J］.Biomed Res Int,2020,2020:8283401.